Cagent Vascular Closes $41M Series D for IVL System

Cagent Vascular closed a $41 million Series D financing co-led by U.S. Venture Partners and Astoria Health Investors. The Wayne, Pennsylvania-based medtech firm also completed the first human-use cases of its Serranator SONIC Intravascular Lithotripsy (IVL) System. The funding and clinical milestone arrive together, giving Cagent Vascular the capital to run the global REMODEL II pivotal trial and launch the device commercially. For investors tracking private medtech, the round tests whether a new serration-based balloon design can challenge Shockwave Medical's dominance in the lithotripsy market.

$41M Series D: REMODEL II Pivotal Trial and SONIC IVL Launch

The Series D proceeds target two specific initiatives. First, the REMODEL II trial will evaluate the Serranator SONIC IVL system in a multicenter, multinational setting for peripheral artery disease. Second, the commercial rollout of the SONIC IVL system, which uses Serration Remodeling Therapy (SRT) to fracture calcified plaque before stenting. Cagent Vascular is the only company with an angioplasty balloon that integrates serrations into the balloon surface, a design intended to crack calcium more predictably than conventional balloons or standard lithotripsy catheters.

The first human-use cases have already been performed. Cagent Vascular reported that the initial procedures with the SONIC IVL system were completed without complication. The company disclosed no specific outcome data beyond successful device delivery and deployment. For a private company in a competitive space–Shockwave Medical's coronary IVL product generated over $1 billion in 2024 sales–the first-case data serves as a procedural proof-of-concept rather than a clinical endpoint. The round also funds the SONIC IVL coronary artery platform, extending the technology into the coronary segment.

REMODEL II Trial as the Next Catalyst for Peripheral Artery Disease

The pivotal study will be the first large-scale evaluation of the Serranator SONIC IVL system in peripheral arteries. Success in REMODEL II would give Cagent Vascular the clinical evidence needed to challenge established players in the estimated $2.5 billion global peripheral artery disease (PAD) treatment market. The trial's enrollment timeline, primary endpoint choice (likely target lesion revascularization or patency), and comparator arm will define the risk-reward for investors following the Series D. A positive readout would also support the company's coronary IVL platform, where Shockwave's product currently dominates.

Cagent Vascular's mission focuses on Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI), two conditions where vessel preparation quality directly affects amputation rates and repeat intervention costs. The SRT approach claims to offer a mechanical advantage over standard lithotripsy by using serrated edges to initiate predictable fractures. Whether that translates into better clinical outcomes in a randomized trial is the central question that REMODEL II must answer.

Serranator Commercial Foundation and the Next Decision Point

Cagent Vascular already has a commercial infrastructure in place. The Serranator portfolio is sold across most major U.S. markets and select international territories. That existing distribution network reduces the go-to-market risk for the SONIC IVL system, provided the device receives regulatory clearance after the trial. The $41 million round also includes participation from existing backers, implying continued insider support. No valuation or revenue figures were disclosed.

The close of a Series D at this size–especially in a venture environment still cautious on medtech–suggests that investors see the SONIC IVL system as a potential threat to the Shockwave monopoly, at least in the peripheral segment. The immediate follow-up catalyst is the first patient enrollment in the REMODEL II trial, which will confirm the timeline for a pivotal data readout. Without a disclosed enrollment timeline, the market will track regulatory filings and investigator site activations.

For investors evaluating medtech opportunities, the question is whether the serration mechanism can replicate the clinical success of lithotripsy while reducing cost or procedure time. The Series D buys Cagent Vascular roughly 18 to 24 months of runway to generate that evidence. If REMODEL II delivers positive results, the company becomes a likely acquisition target for larger cardiovascular device firms. If the trial stumbles, the capital structure resets around a smaller, slower commercial plan. For broader context on how venture-backed medtech companies affect the public stock market analysis landscape, the Cagent Vascular funding round fits a pattern of private firms raising late-stage capital to fund pivotal trials that, if successful, lead to high-multiple M&A exits. The next two quarters will reveal whether the SONIC IVL system's first human-use cases translate into a registrational dataset.